Furthermore, clinical trials using cytokines to decrease Th17 cells or pharmacological interventions with antibodies targeting IL-17 levels or IL-17R function have been performed to ameliorate autoimmune diseases [2,27–29,57–59]. This evidence concerns the gene IL17A and autoimmune disease.